Literature DB >> 7888265

Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients.

M Beghetti1, W Habre, B Friedli, M Berner.   

Abstract

OBJECTIVE: To assess the effect of inhaled nitric oxide (NO) on severe postoperative pulmonary hypertension in children after surgical repair of a congenital heart defect.
DESIGN: A pilot study of NO administration to 7 consecutive children who required adrenergic support and in whom postoperative mean pulmonary artery pressure was more than two thirds of mean systemic pressure and persisted despite alkalotic hyperventilation.
SETTING: Routine care after cardiac surgery for congenital heart disease in a multidisciplinary paediatric intensive care unit.
METHODS: Continuous inhalation of NO, initially at 15 ppm. Therefore, daily attempts at complete weaning or at reducing NO to the lowest effective dose.
RESULTS: In 6 of the 7 children NO inhalation selectively decreased mean (SD) pulmonary artery pressure from 51 (12) to 31 (9) mm Hg (P < 0.05) while mean systemic arterial pressure was unchanged (68 (10) v 71 (7) mm Hg) (NS) and the arteriovenous difference in oxygen content decreased from 6.7 (0.9) to 4.8 (0.8) vol% (P < 0.05). Concomitantly PaO2 increased from 158 (98) to 231 (79) mm Hg) (P < 0.05). The seventh child showed no response to NO up to 80 ppm, could not be weaned from cardiopulmonary bypass, and died in the operating room. In responders, attempts at early weaning from NO inhalation always failed and NO at concentrations of less than 10 ppm was continuously administered for a median of 9.5 days (range 4 to 16 days) until complete weaning was possible from a mean dose of 3.9 (2.9) ppm. Methaemoglobinaemia remained below 2% and nitrogen dioxide concentrations usually ranged from 0.1 to 0.2 ppm. One child later died and five were discharged. A few months after surgery Doppler echocardiography (and catheterisation in one) showed evidence of regression of pulmonary hypertension in all 5.
CONCLUSIONS: Inhalation of NO reduced pulmonary artery pressure in children with severe pulmonary hypertension after cardiac surgery and this effect was maintained over several days at concentrations carrying little risk of toxicity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7888265      PMCID: PMC483758          DOI: 10.1136/hrt.73.1.65

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  15 in total

1.  Safety guidelines for use of nitric oxide.

Authors:  L Foubert; B Fleming; R Latimer; M Jonas; A Oduro; C Borland; T Higenbottam
Journal:  Lancet       Date:  1992-06-27       Impact factor: 79.321

2.  Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.

Authors:  C Frostell; M D Fratacci; J C Wain; R Jones; W M Zapol
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

3.  Negative feedback regulation of endothelial cell function by nitric oxide.

Authors:  G M Buga; J M Griscavage; N E Rogers; L J Ignarro
Journal:  Circ Res       Date:  1993-11       Impact factor: 17.367

4.  Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome.

Authors:  H Gerlach; R Rossaint; D Pappert; K J Falke
Journal:  Eur J Clin Invest       Date:  1993-08       Impact factor: 4.686

5.  Relief of severe pulmonary hypertension after closure of a large ventricular septal defect using low dose inhaled nitric oxide.

Authors:  M Berner; M Beghetti; B Ricou; J C Rouge; R Prêtre; B Friedli
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

6.  Inhaled nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J D Roberts; D M Polaner; P Lang; W M Zapol
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

7.  Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger's syndrome.

Authors:  A T Dinh Xuan; T W Higenbottam; C Clelland; J Pepke-Zaba; G Cremona; J Wallwork
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

8.  Nitric oxide and prostacyclin lower suprasystemic pulmonary hypertension after cardiopulmonary bypass.

Authors:  D Schranz; R Huth; C F Wippermann; S Ritzerfeld; F X Schmitt; H Oelert
Journal:  Eur J Pediatr       Date:  1993-10       Impact factor: 3.183

9.  Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass.

Authors:  D L Wessel; I Adatia; T M Giglia; J E Thompson; T J Kulik
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

10.  Hyperoxia and alkalosis produce pulmonary vasodilation independent of endothelium-derived nitric oxide in newborn lambs.

Authors:  J R Fineman; J Wong; S J Soifer
Journal:  Pediatr Res       Date:  1993-04       Impact factor: 3.756

View more
  25 in total

Review 1.  Inhaled nitric oxide and pulmonary vasoreactivity.

Authors:  M Aranda; R G Pearl
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

2.  Inhaled nitric oxide fraction is influenced by both the site and the mode of administration.

Authors:  E Sieffert; L Ducros; M R Losser; D M Payen
Journal:  J Clin Monit Comput       Date:  1999-12       Impact factor: 2.502

Review 3.  Review of inhaled nitric oxide in the pediatric cardiac surgery setting.

Authors:  Paul A Checchia; Ronald A Bronicki; Brahm Goldstein
Journal:  Pediatr Cardiol       Date:  2012-04       Impact factor: 1.655

4.  UK guidelines for the use of inhaled nitric oxide therapy in adult ICUs. American-European Consensus Conference on ALI/ARDS.

Authors:  B H Cuthbertson; P Dellinger; O J Dyar; T E Evans; T Higenbottam; R Latimer; D Payen; S A Stott; N R Webster; J D Young
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

Review 5.  The pediatric cardiology pharmacopeia: 2013 update.

Authors:  Paul Nicholas Severin; Sawsan Awad; Beth Shields; Joan Hoffman; William Bonney; Edmundo Cortez; Rani Ganesan; Aloka Patel; Steve Barnes; Sean Barnes; Shada Al-Anani; Umang Gupta; Yolandee Bell Cheddar; Ismael E Gonzalez; Kiran Mallula; Hani Ghawi; Suhaib Kazmouz; Salwa Gendi; Ra-id Abdulla
Journal:  Pediatr Cardiol       Date:  2012-11-29       Impact factor: 1.655

Review 6.  Drug treatment of pulmonary hypertension in children.

Authors:  Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

7.  Our paper 20 years later: Inhaled nitric oxide for the acute respiratory distress syndrome--discovery, current understanding, and focussed targets of future applications.

Authors:  R Rossaint; K Lewandowski; W M Zapol
Journal:  Intensive Care Med       Date:  2014-09-09       Impact factor: 17.440

8.  Postoperative Inhaled Nitric Oxide Does Not Decrease Length of Stay in Pediatric Cardiac Surgery Admissions.

Authors:  Joshua Wong; Rohit S Loomba; Lee Evey; Ronald A Bronicki; Saul Flores
Journal:  Pediatr Cardiol       Date:  2019-08-24       Impact factor: 1.655

9.  Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome.

Authors:  W Budts; N Van Pelt; H Gillyns; M Gewillig; F Van De Werf; S Janssens
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

10.  Total anomalous pulmonary venous connection: post operative problems and management.

Authors:  Sandeep Khanna; Minati Choudhury; Usha Kiran
Journal:  Indian J Anaesth       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.